TD Cowen raised the firm’s price target on Myriad Genetics to $30 from $28 and keeps a Hold rating on the shares. The firm said Q2 reflected a good sales beat and they view the results and updated FY 2024 and long-term guides as another step in the right direction to gaining confidence in the sustainability of recent strength, where Street models still don t reflect the outlook.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
- Myriad Genetics appoints Jennifer Fox as CLO
- MYGN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Myriad Genetics announces results from nationwide Cancer Risk Survey
- What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk